A booster dose of the COVID-19 vaccine developed by Pfizer Inc and German partner BioNTech SE was 95.6% effective against the coronavirus when compared to a vaccinated group that did not get the third shot, data from a large study released by the companies showed on Thursday.

The companies in a release said the booster was tested on 10,000 participants aged 16 and older who had received two doses in its earlier trials. A booster administered about 11 months after the second shot had a favorable safety profile and worked against the highly contagious Delta variant of the coronavirus, they said. The data has not been submitted for peer review. The trial results came up a day after the U.S. Food and Drug Administration authorized booster doses of the COVID-19 vaccines from Moderna Inc and Johnson & Johnson and said Americans could choose a different shot from their original inoculation as a booster.

Pfizer had said its two-shot vaccine’s efficacy wanes over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries have already gone ahead with plans to give booster doses.

The companies said they would submit detailed results of the trial for peer-reviewed publication to the FDA, the European Medicines Agency, and other regulatory agencies, as soon as possible.

Source: Reuters

Leave a Reply